Juha T. Klefström

This study identifies TACC3 as a vulnerability in MYC-overexpressing triple-negative breast cancers, showing that its inhibition induces cytotoxicity and inflammatory responses.

This study identifies JQ1 and 45°C as optimal components for a combined chemo-photothermal therapy to induce immunogenic cell death in metastatic breast cancer.

The paper identifies microtubule inhibitors as inducers of immunogenic cell death in MYChigh TNBC, linking MYC-dependent DAMP release to immune activation and tumor protection.

This study identifies enhanced mitochondrial respiration and glutamine-dependent TCA cycle as vulnerabilities in MYChigh breast cancer cells, showing synthetic lethality with complex I inhibitors.

The paper evaluates immunomodulatory drug responses in patient-derived tumor explant models of breast and renal cancer, finding reproducible gene expression and cytokine changes across models.